Track Goldline Pharmaceutical Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: 1.38 %
Low
29.0
High
34.0
1 Month returns: -13.16 %
Low
28.5
High
38.0
1 Year returns: –
3 Year CAGR: –
5 Year CAGR: –
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Goldline Pharmaceutical Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Goldline Pharmaceutical Ltd. Shareholding Pattern
Quarterly breakdown of Goldline Pharmaceutical Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Goldline Pharmaceutical Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Goldline Pharmaceutical Ltd.?
The current share price of Goldline Pharmaceutical Ltd. is ₹ 33.00 as of 7 Oct 2026.
What is the market capitalisation of Goldline Pharmaceutical Ltd.?
The market capitalisation of Goldline Pharmaceutical Ltd. stands at ₹ 31.68 Cr.
What is the PE ratio of Goldline Pharmaceutical Ltd.?
The Price-to-Earnings (PE) ratio of Goldline Pharmaceutical Ltd. is 7.69 as of the latest trailing twelve months data.
What is the ROE and ROCE of Goldline Pharmaceutical Ltd.?
Goldline Pharmaceutical Ltd. has a Return on Equity (ROE) of 33.47% and a Return on Capital Employed (ROCE) of 29.91% as per the latest financial reports.
What is the 52-week high and low of Goldline Pharmaceutical Ltd.?
The 52-week high of Goldline Pharmaceutical Ltd. is - and the 52-week low is -.
What is the dividend yield of Goldline Pharmaceutical Ltd.?
The dividend yield of Goldline Pharmaceutical Ltd. is 0.00% based on the current market price.
What is the FII and DII holding in Goldline Pharmaceutical Ltd.?
Foreign Institutional Investors (FII) hold 5.16%, Domestic Institutional Investors (DII) hold 0.09% and retail/public investors hold 27.76% of Goldline Pharmaceutical Ltd. shares.
What sector does Goldline Pharmaceutical Ltd. belong to?
Goldline Pharmaceutical Ltd. operates in the Healthcare sector.
What is the beta of Goldline Pharmaceutical Ltd.?
The beta of Goldline Pharmaceutical Ltd. is -, indicating its price volatility relative to the broader market.
What is the RSI of Goldline Pharmaceutical Ltd.?
The 14-day Relative Strength Index (RSI) of Goldline Pharmaceutical Ltd. is 41.72, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
Stock Analysis
Fundamental analysis overview of Goldline Pharmaceutical Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Stock is cheap and PE TTM is at a discount to industry median
PE TTM of 7.69 indicates that the stock is cheap on a standalone basis. Discount to industry median P/E is decent at -75.56%
What is P/E Ratio?
Median: 31.46
Value 7.69
-0.84732.63
Negative
Low dividend yield
The company has a low dividend yield of 0.0%
What is Dividend yield?
Neutral
Not enough talking points with neutral stance
Thinly traded (low daily turnover)
The stock is thinly traded with combined (NSE & BSE) daily turnover (21-day average) of 0.100562.
Mar 2026
May 2026
Total Promoter
-
57.29
Indian Promoter
-
57.29
Foreign Promoter
-
-
Institutions
-
12.69
Mutual Funds / UTI
-
-
FI/Bank/Insurance
0.00
0.09
Govt
-
-
FII
0.00
5.16
Other Institutions
0.00
7.44
Non-Institution
-
30.02
Bodies Corporate
-
2.26
Others (incl. Retail)
No. of shareholders
0.00
0
27.76
212
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Name
Month
Transaction
Holding % pre transaction
Average price
Qty.
Transaction value
Amol Laxmikant Mujumdar
Promoter and Director
September-2026
Market Purchase (Acquisition)
1st Sep 2026
29.27 %
₹ 0.00
18.00 k
₹ 0.00
Prashant Shrikrishna Karkare
Director
July-2026
Market Purchase (Acquisition)
29th Jul 2026
0.00 %
₹ 0.00
27.00 k
₹ 0.00
Swapan Khandelwal
Promoter & Director
June-2026
Market Purchase (Acquisition)
23rd Jun 2026
28.65 %
₹ 43.27
60.00 k
₹ 25.96 lac
No corporate action data available.
Company Profile
Overview of Goldline Pharmaceutical Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Goldline Pharmaceutical Limited is an India-based company, which is engaged in the business of marketing pharmaceutical products under the brand name Goldline. The Companys product portfolio is organized into five segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. Goldline Pharma products cater to specialties such as physicians, orthopedics, ENT, chest physicians, general and specialty surgery, gastroenterology, neurology, and urology. Goldline Cardinal products serve medical fields such as physicians, diabetologists, endocrinologists, cardiologists, and general physicians. Goldline Aayushman products cater to medical fields such as pediatricians, child specialists, neonatologists, and general practitioners. Goldline InLife products serve intensivists, critical care consultants, super specialty surgeons, and physicians. Goldline Wellness is a specialized range of products for cancer survivors.
Goldline Pharmaceutical Limited is an India-based company, which is engaged in the business of marketing pharmaceutical products under the brand name Goldline. The Companys product portfolio is organized into five segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and...
Key personnel
Ms. Dipti Sharad Bhusari
Chief Financial Officer
Ms. Ruchi Sanket Modi
Company Secretary, Compliance Officer
Mr. Amol Laxmikant MujumdarD
Executive Chairman of the Board, Managing Director